Actuate Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE: Actuate Therapeutics Secures Half-Million Dollar Private Placement from Bios 2024 Co-Invest
Actuate Therapeutics, Inc. has completed a private placement, raising nearly $500,000 through the sale of common stock and warrants to Bios 2024 Co-Invest, LP.
NASDAQ
SCHEDULE 13D/A: Bios Equity Partners Group Updates Significant Stake in Actuate Therapeutics, Exceeding 50% Beneficial Ownership
An amendment to a Schedule 13D filing reveals that the Bios Equity Partners group, including key individuals Leslie W. Kreis and Aaron G.L. Fletcher, has updated its beneficial ownership in Actuate Therapeutics, Inc., with the group's aggregate stake now exceeding 50% of the common stock.